Vanta Bioscience Limited (VANTABIO.BO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-400.0%

-₹61.16

vs ₹20.39 price

Levered DCF

-₹113.79

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

0.19

Distress zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	101×	-2.93×	-17.44×	-5.6×	784.64×	229.58×	57.23×	139.64×
P/B	0.52×	1.34×	2.66×	2.07×	2.89×	4.3×	2.45×	4.36×
P/S	6.02×	7.11×	4.15×	6.23×	7.38×	10.48×	4.18×	8.03×
EV / EBITDA	47.96×	-20.22×	71.3×	-54.7×	29.29×	34.29×	16.77×	30.53×
Gross margin	94.1%	32.0%	7.3%	-22.9%	48.9%	52.5%	45.2%	55.8%
Operating margin	34.8%	-441.6%	-32.7%	-86.9%	22.9%	28.0%	23.1%	25.0%
Net margin	6.0%	-243.2%	-23.8%	-111.2%	0.9%	4.6%	7.3%	5.8%
Current ratio	1.2×	0.58×	0.75×	0.86×	1.02×	1.34×	2.01×	5.32×
Debt / equity	1.8×	6.72×	4.01×	3.26×	1.87×	1.5×	0.74×	0.6×
Interest coverage	0.81×	-2.13×	-0.55×	-0.86×	0.92×	1.29×	1.63×	1.79×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	0.5%	-45.8%	-15.2%	-37.0%	0.4%	1.9%	4.3%	3.1%
Return on invested capital	1.0%	-11.5%	-4.2%	-6.6%	1.7%	3.3%	5.7%	5.2%
Return on assets	0.2%	-5.6%	-2.7%	-7.7%	0.1%	0.6%	2.1%	1.8%
Free cash flow yield	-117.7%	-65.2%	-1.8%	-97.0%	-20.6%	-17.0%	-15.9%	-8.2%
Earnings yield	1.0%	-34.2%	-5.7%	-17.9%	0.1%	0.4%	1.7%	0.7%
Enterprise value	₹488.8M	₹838.2M	₹1B	₹933.6M	₹1.1B	₹1.4B	₹746.1M	₹1.1B
Net debt / EBITDA	37.23×	-16.85×	42.84×	-33.44×	11.47×	8.39×	3.86×	2.85×
Cash conversion cycle (days)	20,760	1,938	414	512	551	679	746	649